|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300076531 |
|
最近更新日期: Date of Last Refreshed on: |
2023-10-11 10:48:03 |
|
注册时间: Date of Registration: |
2023-10-11 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
TURP的围手术期抗菌药物预防性应用与评估—一项多中心前瞻性随机对照研究 |
|
Public title: |
Antimicrobial Prophylaxis in Transurethral Resection of the Prostate: A multicenter, prospective, randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
TURP的围手术期抗菌药物预防性应用与评估—一项多中心前瞻性随机对照研究 |
|
Scientific title: |
Antimicrobial Prophylaxis in Transurethral Resection of the Prostate: A multicenter, prospective, randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
方露 |
研究负责人: |
方露 |
|
Applicant: |
Fanglu |
Study leader: |
Fanglu |
|
申请注册联系人电话: Applicant telephone: |
+86 136 1569 0228 |
研究负责人电话: Study leader's telephone: |
+86 136 1569 0228 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
fanglu_uro@126.com |
研究负责人电子邮件: Study leader's E-mail: |
fanglu_uro@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
安徽医科大学第二附属医院 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
安徽省合肥市经开区芙蓉路678号 |
研究负责人通讯地址: |
安徽省合肥市经开区芙蓉路678号 |
|
Applicant address: |
The Second Hospital of Anhui Medical University, 678 FuRong Road, Hefei |
Study leader's address: |
The Second Hospital of Anhui Medical University, 678 FuRong Road, Hefei |
|
申请注册联系人邮政编码: Applicant postcode: |
230601 |
研究负责人邮政编码: Study leader's postcode: |
230601 |
|
申请人所在单位: |
安徽医科大学第二附属医院 |
||
|
Applicant's institution: |
The Second Hospital of Anhui Medical University |
||
|
研究负责人所在单位: |
安徽医科大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Hospital of Anhui Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
YX2022-063 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
安徽医科大学第二附属医院医学研究伦理委员会 |
||
|
Name of the ethic committee: |
The Second Hospital of Anhui Medical University, Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-06-10 00:00:00 |
||
|
伦理委员会联系人: |
张静 |
||
|
Contact Name of the ethic committee: |
Zhangjing |
||
|
伦理委员会联系地址: |
安徽省合肥市经开区芙蓉路678号 |
||
|
Contact Address of the ethic committee: |
The Second Hospital of Anhui Medical University, 678 FuRong Road, Hefei |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 551 6380 6061 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
安徽医科大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Hospital of Anhui Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
安徽省合肥市经开区芙蓉路678号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
The Second Hospital of Anhui Medical University, 678 FuRong Road, Hefei |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2021年安徽医科大学第二附属医院临床研究培育计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Clinical research training project of the Second Hospital of Anhui medical university |
||||||||||||||||||||||
|
Target disease: |
Benign prostate hyperplasia |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
验证术前无尿路感染的BPH患者围手术期不预防性应用抗菌药物的安全性,从而降低抗菌药物的使用量,为规范泌尿系统手术中抗菌药物的合理应用提供有力的循证依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
Antibiotic prophylaxis is standard procedure in transurethral resection of the prostate (TURP). We evaluated the necessity of antibiotic (AB) prophylaxis in TURP due to increasing microbial antibiotic resistance. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)55-78岁男性; 2)具有良性前列腺增生外科手术适应证; 3)术前尿常规检查无脓尿,尿培养阴性; 4)术前未保留导尿; 5)术后病理证实为BPH; 6)自愿签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1) Male, 55-78 years old 2) Surgical indications for benign prostatic hyperplasia 3) Preoperative urine routine examination showed no pyuria, and urine culture was negative 4) No catheterization was retained before surgery 5) Postoperative pathology confirmed BPH 6) Voluntary informed consent |
||||||||||||||||||||||
|
排除标准: |
1)严重心肺脑等疾病不能耐受麻醉及手术; 2)合并膀胱结石或膀胱肿瘤; 3)血糖控制不佳的糖尿病患者; 4)使用免疫抑制剂。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Severe heart, lung and brain diseases can not tolerate anesthesia and surgery 2) Complicated with bladder stone or bladder tumor 3) Diabetics with poor blood sugar control 4) The use of immunosuppressive agents |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-07-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2022-08-01 00:00:00 至 To 2023-12-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
受试者充分知情同意后,采用抛硬币方法随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
After the subject fully informed consent, they were randomly assigned by flip a coin |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后6个月内;ResMan 数据平台, http://www.medresman.org.cn. |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Within six months after the trial complete, ResMan, http://www.medresman.org.cn. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF+电子采集及管理系统(ResMan 数据平台) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF+Electronic Data Capture (ResMan) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |